Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.

ABSTRACT: To explore and summarize the association between treatment with tocilizumab and clinical outcomes in COVID-19 patients. We performed a systematic review and meta-analysis (10 RCTs including 3378 patients in the tocilizumab group and 3142 patients in the control group). We systematically searched PubMed and MedRxiv for all RCTs as of June 1, 2021, to assess the benefits and harms of tocilizumab to treat patients with COVID-19. All analyses were carried out using RevMan version 5.4.1. There were nine RCTs published in peer-reviewed journals and one RCTs published as a preprint. The summary RR for all-cause mortality with tocilizumab was 0.89 (95% CI= 0.82-0.96, P= 0.003). There was no significant between-trial heterogeneity (I²= 28%, P= 0.19). However, all pee

SUBMITTER: Peng J 

PROVIDER: S-EPMC8833131 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature